A Role for Interleukin-1 in Septic Shock

  • L. L. Moldawer
  • E. Fischer
  • K. Van Zee
  • W. A. Thompson
  • S. F. Lowry

Abstract

Therapies that can reduce the morbidity and mortality of Gram negative septic shock offer great potential for treatment of the critically-ill patient. Septic shock secondary to Gram negative bacteremia or endotoxemia is characterized by hemodynamic collapse, hypercoagulopathy, multisystem organ failure and death. Despite supportive therapy, mortality still approximates 50%.

Keywords

Placebo Permeability Toxicity Depression Cage 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tracey, K.J., Fong, Y., Hesse, D.G., Manogue, K.R., Lee, A.T., Kuo, G.C., Lowry, S.F., Cerami, A. Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662–664, 1987.PubMedCrossRefGoogle Scholar
  2. 2.
    Hinshaw, L.B., Tekamp-Olson, P., Chang, A.C., Lee, P.A., Taylor, F.B. Jr., Murray, C.K., Peer, G.T., Emerson, T.E., Jr., Passey, R.B., Kuo, G.C. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor. Circ. Shock 30:279–292, 1990.PubMedGoogle Scholar
  3. 3.
    Mathison, J.C., Wolfson, E., Ulevitch, R.J. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J. Clin. Invest. 81:1925–1937, 1988.PubMedCrossRefGoogle Scholar
  4. 4.
    Fong, Y., Tracey, K.J., Moldawer, L.L., Hesse, D.G., Manogue, K.R., Kenny, J., Lee, A.T., Kuo, G.C., Allison, A., Lowry, S.F., Cerami, A. Antibody to cachectin/tumor necrosis factor attenuates interleukin-1 beta and interleukin-6 appearance during overwhelming bacteremia. J. Exp. Med. 170:1627–1633, 1989.PubMedCrossRefGoogle Scholar
  5. 5.
    Okusawa, S., J.A. Gelfand, T. Ikejima, R.J. Connolly, and C.A. Dinarello. Interleukin 1 induces a shock-like state in rabbits. J. Clin. Invest. 81:1162–1172, 1988.PubMedCrossRefGoogle Scholar
  6. 6.
    Waage, A., Espevik, T, Interleukin-1 potentiates the lethal effect of tumor necrosis factor alpha/cachetin in mice. J. Exp. Med. 167:1987–1992, 1988.PubMedCrossRefGoogle Scholar
  7. 7.
    Fischer, E., Marano, M.A., Barber, A., Hudson, A., Lee, K., Rock, C., Hawes, A.S., Thompson, R.C., Hayes, T.V., Anderson, T.D., Benjamin, W.R., Lowry, S.F., Moldawer, L.L. A comparison between the effects of interleukin-1α administration and sublethal endotoxemia in primates. Amer. J. Physiol. 261:R442–452, 1991.PubMedGoogle Scholar
  8. 8.
    Van Zee, K., DeForge, L., Fischer, E., Marano, M.A., Kenney, J.S., Remick, D.G., Lowry, S.F., Moldawer, L.L. IL-8 in septic shock, endotoxemia and following IL-1 administration. J. Immunol. 146:3478–3482, 1991.PubMedGoogle Scholar
  9. 9.
    Tracey, K.J., Lowry, S.F., Fahey, T.J., III, Albert, J.D., Fong, Y., Hesse, D., Beutler, B., Manogue, K.R., Calvano, S., Wei, H. Cerami, A., Shires, G.T. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg. Gyn. Obstet. 164:415–422, 1987.Google Scholar
  10. 10.
    Tracey, K.J., B. Beutler, S.F. Lowry, J. Merryweather, S. Wolpe, I.W. Milsark, R.J. Hariri, T.J. Fahey III, A. Zentella, J.D. Albert, G.T. Shires, and A. Cerami. Shock and tissue injury induced by recombinant human cachectin. Science (USA) 234:470–474, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Wakabayashi, G., Gelfand, J.A., Burke, J.F., Dinarello, C.A. A specific receptor antagonist for interleukin-1 prevents E. coli induced septic shock in rabbits. FASEB J. 5: 338–343, 1991.PubMedGoogle Scholar
  12. 12.
    Chizzonite, R., T. Truitt, P.L. Kilian, A.S. Stern, P. Nunes, K.P. Parker, K.L. Kaffka, A.O. Chua, D.K. Lugg, and U. Gubler. Two high-affinity interleukin 1 receptors represent separate gene products. Proc. Natl. Acad. Sci.(USA) 86:8029–8033, 1989.PubMedCrossRefGoogle Scholar
  13. 13.
    Arend, W.P., F.G. Joslin, R.C. Thompson, and C.H. Hannum. An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. J. Immunol. 143: 1851–1858, 1989.PubMedGoogle Scholar
  14. 14.
    Eisenberg, S.P., R.J. Evans, W.P. Arend, E. Verderber, M.T. Brewer, C.H. Hannum, and R.C. Thompson. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343: 341–346, 1990.PubMedCrossRefGoogle Scholar
  15. 15.
    Ohlsson, K., P. Bjork, M. Bergenfeldt, R. Hageman, and R.C. Thompson. An interleukin-1 receptor antagonist reduces mortality in endotoxin shock. Nature 348: 550–552, 1990.PubMedCrossRefGoogle Scholar
  16. 16.
    Fischer, E., Marano, M.A., Van Zee, K.J., Rock, C.S., Hawes, A.S., Thompson, W.A., DeForge, L., Kenney, J.S., Remick, D.G., Bloedow, D.C., Thompson, R.C., Lowry, S.F., Moldawer, L.L. Interleukin-1 receptor blockade improves survival and hemodynamic performance in E. coli septic shock, but fails to alter host responses to sublethal endotoxemia. J. Clin. Invest. 89:1551–1557, 1992.PubMedCrossRefGoogle Scholar
  17. 17.
    Dinarello, C.A., T. Ikejima, S.J.C. Warner, S.F. Orencole, G. Lonnemann, J.G. Cannon, and P. Libby. 1987. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol. 139: 1902–1910.PubMedGoogle Scholar
  18. 18.
    Fisher, C.J., Jr., Slotman, G.J., Opal, S., Pribble, J., Stiles, D., Catalano, M., and the IL-1ra Sepsis Study Group. Intcrleukin-1 receptor antagonist reduces mortality in patients with sepsis syndrome. (Abstract) Amer. Coll. Chest Phys., 1991.Google Scholar
  19. 19.
    Fischer, E., Van Zee, K.J., Maranon, M.A., Rock, C.S., Kenney, J.S., Poutsiaka, D.D., Dinarello, C.A., Lowry, S.F., Moldawer, L.L. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79:2196–2200, 1992.PubMedGoogle Scholar
  20. 20.
    Dinarello, C.A., Rosenwasser, L.J., Wolff, S.M. Demonstration of a circulating supressor factor of thymocyte proliferation during endotoxin fever in humans. J. Immunol. 127:2517–2522, 1981.PubMedGoogle Scholar
  21. 21.
    Spinas, G.A., Bloesch, D., Kaufmann, M.T., Keller, R., Dayer, J-M. Induction of plasma inhibitors of interlcukin 1 and TNF-α activity by endotoxin administration to normal humans. Amer. J. Physiol. 259:993–998, 1990.Google Scholar
  22. 22.
    Arend, W.P., Welgus, H.G., Thompson, R.C., Eisenberg, S.P. Biological properties of recombinant human monocyte-derived interlcukin 1 receptor antagonist. J. Clin. Invest. 85:1694–1700, 1990.PubMedCrossRefGoogle Scholar
  23. 23.
    McIntyre, K.W., Stepan, G.J., Kolinsky, K.D., Benjamin, W.R., Plocinski, J.M., Kaffka, K.L., Campen, C.A., Chizzonite, R.A., Kilian, P.L. Inhibition of interlcukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J. Exp. Med. 173:931–939, 1991.PubMedCrossRefGoogle Scholar
  24. 24.
    Ginsberg, H., Moldawer, L.L., Sehgal, P.B., Redington, M., Kilian, P.L., Chanock, R.M., Prince, G.A. A unique mouse model to investigate the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. (USA) 88:1651–1656, 1991.PubMedCrossRefGoogle Scholar
  25. 25.
    Cannon, J.G., Tompkins, R.G., Gelfand, J.A., Michie, H.R., Stanford, G.G., Van der Meer, J.W.M., Endres, S., Lonnemann, G., Corsetti, J., Chernow, B., Wolfe, S.M., Dinarello, C.A. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. infect. Diseases 161:79–84, 1990.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • L. L. Moldawer
    • 1
  • E. Fischer
    • 1
  • K. Van Zee
    • 1
  • W. A. Thompson
    • 1
  • S. F. Lowry
    • 1
  1. 1.Laboratory of Surgical Metabolism, Department of SurgeryCornell University Medical CollegeNew YorkUSA

Personalised recommendations